{"key":"op_800_KR","page":{"url":"https://ua.bookimed.com/clinics/country=republic-of-korea/procedure=car-t-cell-therapy/","procedure":{"id":800,"slug":"car-t-cell-therapy","name":"CAR T-клітинна терапія","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"hematology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":36,"iso":"KR","name":"Південна Корея"},"currency":"USD","data_date":"2026-10-26"},"pages":{"clinics_url":"https://ua.bookimed.com/clinics/country=republic-of-korea/procedure=car-t-cell-therapy/","cost_url":"https://ua.bookimed.com/clinics/country=republic-of-korea/procedure=car-t-cell-therapy/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":220000,"to":300000,"avg":{"status":"missing","reason":"no_offers"},"us":{"from":420000,"to":540000},"uk":{"from":330000,"to":420000},"by_technique":{"status":"missing","reason":"not_collected"},"by_city":[{"city":"Сеул","from":280000}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":90000,"to":150000},{"country_iso":"FR","from":295000,"to":385000},{"country_iso":"GB","from":330000,"to":420000},{"country_iso":"US","from":420000,"to":540000},{"country_iso":"IL","from":84000,"to":405000},{"country_iso":"TR","from":150000,"to":220000},{"country_iso":"MX","from":120000,"to":185000},{"country_iso":"DE","from":285000,"to":365000},{"country_iso":"CA","from":340000,"to":470000},{"country_iso":"AE","from":190000,"to":310000},{"country_iso":"TH","from":150000,"to":220000},{"country_iso":"PL","from":165000,"to":230000},{"country_iso":"CZ","from":150000,"to":195000},{"country_iso":"AT","from":280000,"to":365000},{"country_iso":"ES","from":380000,"to":520000},{"country_iso":"IT","from":400000,"to":650000},{"country_iso":"CN","from":275000,"to":319000},{"country_iso":"AU","from":330000,"to":420000},{"country_iso":"IN","from":38000,"to":70000},{"country_iso":"MY","from":120000,"to":180000},{"country_iso":"VN","from":150000,"to":230000},{"country_iso":"BR","from":280000,"to":400000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":48,"variant":">=15%"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":1,"items":[{"id":262,"name":"Samsung Medical Center","city":"Seoul","rating":4.5,"reviews_count":25,"accreditations":["International Organization for Standardization","Korean Institute for Healthcare Accreditation","World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2022 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek"],"rank":1,"has_procedure":true,"why_ranked":"Asia's largest cancer center with 78 oncology beds, 50,000+ patients treated, and 17 cancer-specific departments. On-site Research Institute runs clinical trials for emerging CAR T therapies.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":{"status":"missing","reason":"not_collected"},"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":328,"slug":"seoul","name":"Сеул","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":280000,"profile":{"city_type":"Capital of Republic of Korea","access":["Incheon Airport (ICN), 48 km west of Seoul","Gimpo Airport (GMP), 15 km west of central Seoul"],"sources":["https://en.wikipedia.org/wiki/Seoul","https://en.wikipedia.org/wiki/Incheon_International_Airport","https://en.wikipedia.org/wiki/Gimpo_International_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":{"status":"missing","reason":"no_offers"},"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":{"status":"missing","reason":"no_offers"},"packages":{"status":"missing","reason":"no_offers"},"related_packages":{"status":"missing","reason":"no_offers"},"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"operation_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"hospital_nights":{"value":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"source":"parsed_details"},"treatment_conditions":["inpatient"],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"horizon":"Best response, typically assessed at 1-3 months after infusion","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"missing","reason":"not_collected"},"prep_in_advance":{"status":"missing","reason":"not_collected"},"visit_and_day":{"status":"missing","reason":"not_collected"},"if_something_changes":{"status":"missing","reason":"not_collected"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"days_in_clinic":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","revision_rate_pct":null,"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"unit":"percent","horizon":"Best response, typically assessed at 1-3 months after infusion","evidence_status":"limited","population":"Adults with relapsed/refractory LBCL after two or more prior lines"},"techniques":[{"name":"Autologous CD19-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"name":"Autologous BCMA-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","recovery":"Similar monitoring; prolonged cytopenias are common."}],"treatment_conditions":["inpatient"],"treatment_duration_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"initial_assessment_documents":["Pathology report with CD19 or BCMA status","Summary of prior treatment lines and responses","Recent PET-CT or MRI report","Bone marrow biopsy report","Recent CBC, kidney and liver function tests","Echocardiogram report (if available)"],"travel_trips":{"min":1,"max":2,"one_trip_possible":true,"qualifier":"Cell collection, then 3-9 weeks manufacturing, usually at home; return for infusion and 4+ weeks nearby. One trip means staying."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":null,"prep_in_advance":null,"visit_and_day":null,"if_something_changes":null}},"techniques":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Similar monitoring; prolonged cytopenias are common."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"ok","items":[{"id":"Y1","text":"Republic of Korea runs a medical call center where consultants advise overseas patients in several languages around the clock","specialties":[],"source":{"url":"https://www.khidi.or.kr/board?menuId=MENU00807","host":"khidi.or.kr","quote":"Professional consultants provide advices in Korean, English, Japanese, Chinese, Russian and Arabic 24 hours daily.","tier":"government","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2027-05-10","version":1},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK travelers can enter Republic of Korea for up to 90 days for short-term business or tourism","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/entry-requirements","host":"gov.uk","quote":"You can enter South Korea for up to 90 days for short-term business or tourism.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"US passport holders need a visa for stays in Republic of Korea longer than 90 days and for purposes other than tourism or business, including employment","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"Visa required for all other purposes, including employment, teaching English, and for stays longer than 90 days.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"For a tourist stay of up to 90 days in Republic of Korea, the passport must expire after the date you leave","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/entry-requirements","host":"gov.uk","quote":"To enter South Korea as a tourist for up to 90 days, your passport must have an ‘expiry date’ after the date you are leaving South Korea.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A valid U.S. passport is required to enter Republic of Korea","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"You must have a valid U.S. passport to enter Korea.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"medicines","audience":"all","volatile":false,"text":"Republic of Korea customs allow small amounts of medication for personal use, if kept in carry-on baggage","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/health","host":"gov.uk","quote":"South Korean customs authorities allow you to bring small amounts of medication for your personal use, if it is kept in carry-on baggage.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V6","item":"hospital_payment","audience":"all","volatile":false,"text":"In Republic of Korea, health care providers usually require payment before treatment or will not release a patient until hospital bills are paid","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"In most cases, health care providers will require payment in advance of treatment or will not release a patient until hospital bills are paid.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V7","item":"emergency_number","audience":"all","volatile":false,"text":"In Republic of Korea, call 119 and ask for an ambulance","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/health","host":"gov.uk","quote":"Call 119 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["austria","china","germany","israel","italy","lithuania","spain","thailand","turkey","united-kingdom","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.5,"count":25,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>CAR T-cell therapy in the Republic of Korea typically costs from _op_800_price_from_ to _op_800_price_to_. The total price depends on the specific drug used, hospital stay duration, and side-effect monitoring. In the United States, patients pay _price_compare_US_average_ on average for this treatment. South Korea offers savings of approximately _price_percent_discount_%. Costs generally cover cell collection, genetic engineering, and the infusion process.</p>\n\n<ul>\n<li><strong>Hospitalization and monitoring:</strong> Typically clinical stays last 20 to 21 days for safety.</li>\n<li><strong>Government insurance impact:</strong> Insured residents may see out-of-pocket costs drop by over 95%.</li>\n<li><strong>Destination hubs:</strong> Most advanced CAR T-cell treatments are concentrated in Seoul medical centers.</li>\n<li><strong>Ancillary medical services:</strong> Costs include intensive care monitoring for potential cytokine release syndrome management.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Choosing a high-volume center like Samsung Medical Center provides access to presidential-standard care. This facility serves over 2,000,000 patients annually and holds KOIHA accreditation. The hospital integrates Da Vinci systems and Novalis technology within its Comprehensive Cancer Center. International patients benefit from standardized protocols that match US quality at a significantly lower price point. For those without local insurance, Seoul remains the most cost-effective hub for Kymriah therapy.</p>","faq":[{"q":"Which centers in South Korea are qualified to provide CAR T-cell therapy?","a":"<p>Qualified centers in South Korea must receive Ministry of Food and Drug Safety approval to administer CAR T-cell therapy. Primary authorized facilities include Samsung Medical Center, Seoul National University Hospital, and Seoul St. Mary Hospital. These institutions manage commercial products like Kymriah for lymphoma and leukemia patients.</p> <ul> <li><strong>Samsung Medical Center:</strong> Established the first dedicated CAR T-Cell Center in South Korea in 2021.</li> <li><strong>Seoul National University:</strong> First hospital authorized to produce CAR T-cells internally for pediatric leukemia cases.</li> <li><strong>Seoul St. Mary:</strong> Features an on-site GMP cell processing center for advanced immune cell research.</li> <li><strong>Regulatory compliance:</strong> Facilities must strictly follow the Advanced Biological Product Safety Act for certification.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Samsung Medical Center serves over 2,000,000 patients annually and maintains a presidential-tier infrastructure. This high volume translates to significant experience in complex oncology. Their early adoption of a dedicated center makes them a leader in managing cytokine release syndrome. This specialized care is vital for patient safety during the aggressive CAR T-cell infusion phase.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the need for official verification. They recommend contacting oncology departments directly to confirm current KFDA approval status for specific therapies. Many suggest budgeting over $300,000 and planning for a 6-week stay.</p>"},{"q":"What CAR T-cell products are commercially approved in the Republic of Korea?","a":"<p>South Korea's Ministry of Food and Drug Safety has approved four major CAR T-cell therapies: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Carvykti (ciltacabtagene autoleucel), and Rimqarto (anbalcabtagene autoleucel). These products treat specific lymphomas and multiple myeloma. Administration occurs at specialized centers like Samsung Medical Center.</p> <ul> <li><strong>Kymriah (Novartis):</strong> Approved in 2021 for pediatric ALL and adult DLBCL.</li> <li><strong>Yescarta (Gilead):</strong> Treats relapsed large B-cell lymphoma and primary mediastinal lymphoma.</li> <li><strong>Carvykti (Janssen):</strong> Indicated for adult patients with relapsed or refractory multiple myeloma.</li> <li><strong>Rimqarto (Curocell):</strong> The first homegrown Korean CAR T-cell drug targeting CD19.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While approvals are increasing, manufacturing logistics remain a significant bottleneck. Data shows patients often wait over 6 months for imported products. Top centers like Samsung Medical Center manage these timelines better due to high patient volumes. They serve over 2,000,000 patients annually and have established apheresis protocols.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the need to verify hospital capabilities early. They often report that insurance coverage lags behind regulatory approval, making out-of-pocket costs a major concern.</p>"},{"q":"Which hematologic malignancies are reimbursed for CAR T-cell therapy under Korea’s National Health Insurance?","a":"<p>South Korea National Health Insurance covers CAR T-cell therapy primarily for relapsed or refractory diffuse large B-cell lymphoma and pediatric B-cell acute lymphoblastic leukemia. Coverage usually applies starting from third-line treatment under strict National Health Insurance Service guidelines at accredited medical centers.</p> <ul> <li><strong>Large B-cell lymphoma:</strong> Reimbursed as third-line therapy for adult patients with relapsed or refractory disease.</li> <li><strong>Acute lymphoblastic leukemia:</strong> Covered for pediatric and young adult patients up to 25 years old.</li> <li><strong>Mantle cell lymphoma:</strong> Benefits expanded in 2022 to include this specific hematologic malignancy.</li> <li><strong>Follicular lymphoma:</strong> Approved for clinical use but reimbursement varies significantly by individual case.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Samsung Medical Center serves over 2,000,000 patients annually and holds KOIHA accreditation for safety. Their high volume suggests they manage the complex National Health Insurance reimbursement and hospital-level approvals efficiently. Patients should verify their specific malignancy against the latest risk-sharing agreements at such high-capacity centers.</p> <p><strong>Patient Consensus:</strong> Patients report that while pediatric leukemia coverage is reliable, many adults with multiple myeloma face private costs. Most advise preparing for a 10% to 20% copay even when insurance approves the treatment.</p>"},{"q":"What ongoing CAR T-cell clinical trials are recruiting in South Korea?","a":"<p>South Korea actively recruits for CAR T-cell clinical trials targeting lymphoma, leukemia, and liver cancer. Prominent studies include the ALPHA3 trial for B-cell lymphoma and the EU307 phase 1 trial for hepatocellular carcinoma. Enrollment centers include Samsung Medical Center and Seoul National University Hospital.</p> <ul> <li><strong>Hematologic malignancies:</strong> The ALPHA3 trial evaluates first-line consolidation for large B-cell lymphoma.</li> <li><strong>Leukemia research:</strong> Anbal-cel phase 2 trials investigate treatments for adult acute lymphoblastic leukemia.</li> <li><strong>Solid tumors:</strong> EU307 phase 1 tests anti-GPC3 therapy for advanced liver cancer patients.</li> <li><strong>Autoimmune applications:</strong> Clinics recruit for low-dose CAR-T trials treating refractory Systemic Lupus Erythematosus.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many global trials use ClinicalTrials.gov, South Korean centers often prioritize the local CRIS registry. Samsung Medical Center, which serves over 2,000,000 patients annually, frequently operates internal trial pipelines. Checking their specific Cancer Center listings usually reveals more active slots than international databases.</p> <p><strong>Patient Consensus:</strong> Many find that trial information is mainly available in Korean. Direct contact with tier-1 hospital international departments is more effective than searching public online listings.</p>"}],"h2":[{"text":"Яка вартість CAR T-клітинної терапії в Південній Кореї?","kind":"content"},{"text":"Переваги та гарантії Bookimed","kind":"content"},{"text":"Ваш особистий лікар-координатор Bookimed","kind":"content"},{"text":"Дізнайтеся про найкращі клініки з CAR T-клітинної терапії у Південній Кореї: 1 перевірена клініка та ціни","kind":"content"},{"text":"Огляд процедури CAR T-клітинна терапія в Південній Кореї","kind":"content"},{"text":"Отримайте медичну консультацію щодо CAR T-клітинної терапії в Південній Кореї: Обирайте серед найкращих фахівців у галузі","kind":"content"},{"text":"Корисні статті","kind":"content"},{"text":"Поділитися цим контентом","kind":"content"},{"text":"Відеоісторії пацієнтів Bookimed","kind":"content"},{"text":"FAQ з car t-клітинної терапії в Південній Кореї","kind":"content"},{"text":"Отримати безкоштовну консультацію","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}